Lessons Learned from the Reconstruction of the 1918 Pandemic Adolfo García-Sastre, PhD Professor of Microbiology Mount Sinai School of Medicine.

Slides:

Advertisements

Similar presentations

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research Working Group 8 Virus Transmission: Understanding and Predicting Pandemic Risk.

Advertisements

WORKING GROUP 1 Influenza Virulence and Antigenic Change Chairperson – Robert Webster Briefer – Peter Palese Rapporteur – Robert Lamb.

Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian virus Vaccine 2007 Huoying Shi, Xiu Fan Liu, Xiaorong Zhang,

PANDEMIC INFLUENZA VIRUSES: PAST AND FUTURE PETER PALESE DEPARTMENT OF MICROBIOLOGY MOUNT SINAI SCHOOL OF MEDICINE, NEW YORK ISTANBUL, JULY 11, 2011.

Pathogenicity and transmissibility of the 1918 Spanish influenza pandemic virus Terrence Tumpey Influenza Division Centers for Disease Control and Prevention.

The Antiviral Activity of Oseltamivir against H5N1 Human A/Vietnam/1203/04 and A/Turkey/15/06 Influenza Viruses in Ferrets Elena Govorkova, N.A. Ilyushina,

1 The Basic Problem: Dual-Use Research Kathryn Nixdorff Department of Microbiology and Genetics Darmstadt University of Technology, Germany.

80% Influenza A — H3N2 (some H1N1) 20 % influenza B (orthomyoxiviridae – seals and humans only) Deaths above epidemic threshold – 50% hospitalizations.

Influenza Sara Finestone April 8, The influenza virus causes 3-5 million cases of severe illness and up to 500,000 deaths annually.

AVIANAVIAN FLUFLU Ginny Codd Viruses: Infection and Ecology.

Avian Influenza H5N1: Vaccination Against a Pandemic.

Influenza Vaccination

Bureau of Emergency Preparedness and Response 88 Years of Influenza Pandemics in 15 Minutes Peter C. Kelly, M.D. Arizona Dept. of Health Services.

NS 2 Lipid Bilayer NA (Neuraminidase) HA (Hemagglutinin) M 2 (Ion channel) M 1 (Matrix protein) NP (Nucleocapsid) PB1, PB2, PA (Transcriptase complex)

DR MOHAMMED ARIF. ASSOCIATE PROFESSOR. CONSULTANT VIROLOGIST. HEAD OF THE VIROLOGY UNIT. Viral infection of the respiratory tract -- 2.

Influenza Chapter 39. Causative Agents Influenza A virus Family Orthomyxoviridae Negative-stranded RNA genome Genome divided into 8 gene segments Spiked.

Presented by Jan Haas Institute for Immunology.

Update on Influenza A(H5N1) Activity in Asia Nancy J. Cox, Ph.D. Chief, Influenza Branch National Center for Infectious Diseases Centers for Disease Control.

Influenza Vaccine Development

Pandemic Influenza; A Harbinger of Things to Come Michael T Osterholm PhD, MPH Director, Center for Infectious Disease Research and Policy Associate Director,

Hugh B. Fackrell Filename: orthomyx.ppt

4th Year MPharm SRP: Introduction to Pseudotype Viruses

Emerging Viruses BY PLAN A. Topic Questions  Why are these new viruses more harmful compared to the previous form of the virus?  Why is it so difficult.

The Flu Rapid Reading Exercise. The Flu Every year, 10 percent to 20 percent of Americans get sick with the flu (influenza). For most people, the fever,

April 25, 2009 Mexico Shuts Some Schools Amid Deadly Flu Outbreak Mexico’s flu season is usually over by now, but health officials have noticed a significant.

Misconduct Case Study Our story so far: Peter:4 th -year grad. student makes mice lacking SLAM gene several cell types have abnormal function Sally:4 th.

Using Comparative Genomics to Explore the Genetic Code of Influenza Sangeeta Venkatachalam.

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

ACKNOWLEDGMENTS USD Animal Resource Center Jonathan A. McCullers (St. Jude Children’s Research Hospital) for providing viruses SD-BRIN Undergraduate Fellows.

Influenza A/H1N1 W. Rose H1N1 is a subtype of influenza type A Influenza types B and C also exist but less common, less infectious, and drift.

Influenza Today Joseph Mester, Ph.D. September 24, 2009.

INTRODUCTION Cause RTI Cause RTI Genetic variation (shift and drift) Genetic variation (shift and drift) Estimated million deaths worldwide in pandemic.

Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Pandemic Influenza A (H1N1) Virology Update Nancy Cox, PhD Alexander.

A Systems Approach to Infectious Disease Research: Influenza Develop a molecular network model of the interaction between influenza virus and the innate.

John R. LaMontagne Memorial Symposium on Pandemic Influenza Research April 4-5, 2005 Institute of Medicine Working Group One: Influenza Virulence and Antigenic.

REASSORTMENT OF INFLUENZA VIRUS

Sendai virus: Illuminating parainfluenza virus dynamics in living animals Charles J. Russell, PhD postdoc: Crystal Burke, PhD Funding: NIAID R01AI

Influenza H1N1 A: A close insight Dr. Mustafa Ababneh Molecular Virologist.

Emerging Diseases Lecture 12: Influenza Virus and the 1918 Pandemic 12.1 Overview 12.2 The pathogen-Influenza Virus A 12.3: Naming System 12.4: A Disease.

It’s Just Not the Flu Anymore Rick Hong, MD Associate Chairman CCHS EMC Medical Director, PHPS.

1 INFLUENZA VIRUS. 2 ‘FLU’ True influenza –influenza virus A or influenza virus B (or influenza virus C infections - much milder) Febrile (showing signs.

The New Influenza A/H1N1 Isabelle Thomas May 28-29, 2009 Brussels,

In the name of God. Summer School Influenza Unit, Pasteur Institute of Iran summer 2013 Summer School.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

Interferons Induction of synthesis Induction of antiviral activity Antiviral activities induced by interferons  and  Antiviral activities induced by.

Transmission of 2009 H1N1 Influenza Viruses in Ferrets Terrence Tumpey Immunology and Pathogenesis Branch Influenza Division, CDC EM of CA/04/2009 – CDC/C.S.

EXPLORING INFLUENZA VACCINE PRODUCTION TECHNOLOGIES- PRESENT AND FUTURE Gaurav Gupta, Zydus Cadila, Ahmedabad.

Methods in Virology.

Viral vaccines .

Anti-influenza activity of dihydroquercetin from Larix sibirica (L.) on the model of lethal influenza virus infection. Zarubaev V.V. †, Garshinina A.V.

Will it be just a scare … or a scar on human history? Bird flu.

IM010 IDO1 and TNFRSF1B Knockout (KO) Pilot Part 1: MLD 50 analysis Part 2: Tissue collection for further analysis IDO1 HPAI H5N1 and SARS common bottleneck.

Orthomyxoviridae Is enveloped virus, helical nucleocapsid

Emerging Diseases Lecture 12: Influenza Virus and the 1918 Pandemic

Orthomyxoviridae Influenza viruses

Emerging Diseases Lecture 12: Influenza Virus and the 1918 Pandemic

Influenza Virus: Evolution in real time

Jennifer R. Hamilton, Gayathri Vijayakumar, Peter Palese Cell Reports

Emerging Diseases Lecture 12: Influenza Virus and the 1918 Pandemic

(A) Weight loss curves following intranasal infection of different mouse groups with COBRA, seasonal, or pandemic influenza viruses. (A) Weight loss curves.

Influenza A Virus PB1-F2: A Small Protein with a Big Punch

Volume 26, Issue 2, Pages (February 2018)

Volume 4, Issue 3, Pages (September 2008)

Hemagglutinin-targeting Artificial MicroRNAs Expressed by Adenovirus Protect Mice From Different Clades of H5N1 Infection Xinying Tang, Hongbo Zhang,

Development of Effective Vaccines against Pandemic Influenza

Melissa B. Uccellini, Adolfo García-Sastre Cell Reports

Volume 46, Issue 4, Pages (April 2017)

Molecular Therapy - Nucleic Acids

Cross-protection against variants within a subtype after intranasal immunization with vaccine from MDCK cell-adapted Vac-3 P22. Cross-protection against.

Presentation transcript:

Lessons Learned from the Reconstruction of the 1918 Pandemic Adolfo García-Sastre, PhD Professor of Microbiology Mount Sinai School of Medicine

Armed Forces Institute of Pathology, Jeffery K. Taubenberger Washington DC Mount Sinai School of Medicine, Adolfo García-Sastre New YorkPeter Palese Christopher F. Basler CDCTerrence M. Tumpey USDA, Athens, Georgia David E. Swayne University of Washington, SeattleMichael G. Katze Scripps Research Institute, La JollaIan A. Wilson James Stevens NIH/NIAID support: P01 AI Lessons Learned from the Reconstruction of the 1918 Virus Collaborative effort among different research groups and institutions

U.S. Life Expectancy By Age 1900 ‘30 ‘50‘70‘ Flu Epidemic

Influenza and Pneumonia Deaths by Age Specific Death Rate

Why Study the 1918 Virus? The 1918 virus contains determinants responsible for its success as a pandemic virus The 1918 virus contains virulence determinants that are not understood A new 1918-like virus may evolve The knowledge of these determinants will allow us to better recognize the pandemic potential of circulating animal viruses and will provide us with novel targets for therapeutic and prophylactic intervention

Phenotypic characterization in: Tissue culture Animal models Signatures of Virulence of the 1918 Influenza Virus Gene sequencing Gene reconstruction Pathological specimen (circa 1918)..... Reverse genetics

1918 Influenza AFIP Lung Block

Lung Tissue Sample (1918) Brevig Mission, AK

Reconstruction of 1918 Influenza Virus Genes Clone, Sequence and Repair Final Product

Plasmid-only Influenza A Virus Rescue vRNA expression plasmidsProtein expression plasmids Transfection POL IR R R R R PB2 PB1 PA HA NP NA M NS-1918 POL II POL IRPOL IIpA POL I RPOL IIpA POL IRPOL IIpA PB2 PB1 PA NP 6:2 reassortant virus

Texas/36/91 >6 Tx/91: PB2, PB1, PA, NP, M, NS 1918: HA, NA 4.75 Tx/91: PB2, PB1, PA 1918: HA, NP, NA, M, NS “Spanish” flu MLD 50 ? Mouse Lethal Dose 50 (log) of Viruses Bearing 1918 Genes

M-1918 NS-1918 Plasmid-only Influenza A Virus Rescue Transfection POL IR R R R R R R R vRNA expression plasmids PB PB PA-1918 HA-1918 NP-1918 NA-1918 POL II pA Protein expression plasmids PB2 PB1 PA NP Spanish flu

Influenza A/CDC/1918 Virus

Intranasal Inoculation of Mice, 106 pfu % Survival Days after infection Tx/ :3 Tx/ :HA Tx/91 Viral titers in lungs, day pfu 10 6 pfu 10 8 pfu 10 5 pfu

Virulence of the 1918 Virus: MLD50 Log pfu Texas/36/91 >6 Tx/91: PB2, PB1, PA, NP, M, NS 1918: HA, NA 4.75 Tx/91: PB2, PB1, PA 1918: HA, NP, NA, M. NS “Spanish” flu Tx/91: HA >6

Virulence of the 1918 Virus: ELD50 Log pfu Texas/36/91 >7 Tx/91: PB2, PB1, PA, NP, M, NS 1918: HA, NA Tx/91: PB2, PB1, PA 1918: HA, NP, NA, M. NS 1918 “Spanish” flu Tx/91: HA >7

The 1918 Virus Grows to High Titers in Human Bronchial Epithelial Cells (Calu-3) :3 Tx/91 Tx/91 Time (h post-infection) Log EID 50 /ml

The 1918 NA Allows Growth Without Trypsin Other genes NA Titer in MDCK cells + trypsin (pfu/ml) Titer in MDCK cells - trypsin (pfu/ml) Tx/ x x x 10 8 Tx/ x x 10 7

Oseltamivir Protects Mice from a Lethal Challenge with 1918 HA/1918 NA Virus Percent Survival

Rimantadine Protects Mice from a Lethal Challenge with 1918 M Virus Percent Survival

New Cal/99 PR8/34 Texas/91 Sw/Iowa/30 Protective Killed Inactivated Vaccines Against the 1918 HA/1918 NA Virus % Survival PBS Days post-challenge with 1918HA/NA virus X-31(H3N2) 1918 HA/NA

1.The 1918 virus is the only known human influenza virus lethal to mice and embryonated eggs 2.The glycoprotein and polymerase genes of the virus contribute to enhanced virulence 3.Alveolar macrophages and neutrophils have a protective role 4.A single amino acid change in HA changes receptor specificity 5.Viruses containing 1918 genes are sensitive to existing antivirals 6.H1N1 based vaccines are protective 1918 VIRUS What do we know now? Would a 1918-like HIN1 virus be today as lethal as in 1918?

H1N1 pre-existing immunity 1918 Influenza and Pneumonia Deaths by Age <11 to 45 to >85 Age Divisions Specific Death Rate

Potential Ways to Fight a Highly Virulent 1918-like Pandemic Virus The existing antivirals and conventional vaccines will have beneficial effects (with the caveat that it will be difficult to have these products generated in large quantities at this moment) Consider HA and polymerase genes as targets for new antivirals Consider strategies that immunoregulate function of alveolar macrophages

Alicia Solorzano Luis Martinez Patricia AguilarJohn Kash Laurel GlaserDmitriy Zamarin Stacey Schultz-CherryHui Zeng Jacqueline KatzNancy Cox NIAID Biodefense Grants P01 AI58113 U54 AI57158 (NBC) U19 AI62623 (CIVIA)